ES
ClosedVancouver, Canada · Founded 2009 · $86.2M raised
- Headquarters
- Vancouver
- Employees
- 11–50
- Founded
- 2009
- Business Model
- B2B
- Website
- essapharma.com
- Total Funding
- $86.2M
- Last Round
- $49.0M Corporate RoundAug 2020
- Rounds
- 3
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
ESSA Pharma Inc. (essapharma.com) was a Vancouver-based clinical-stage pharmaceutical company, founded in 2009, that developed novel therapies for prostate cancer, most notably the drug candidate EPI-7386. In 2025 ESSA discontinued its clinical development programs, wound down R&D operations, and distributed approximately $80 million in cash to shareholders following investor pressure to liquidate. Xeno Acquisition Corp., a subsidiary of XenoTherapeutics, completed its acquisition of ESSA's remaining corporate shell on October 7, 2025, after which ESSA delisted from Nasdaq; the company's own press materials now describe it as "previously focused" on prostate cancer therapies.
Summary
ES is a Biotech company based in Vancouver, Canada, founded in 2009. It has raised $86.2M in total across 3 rounds, most recently a $49.0M Corporate Round in Aug 2020. Investors include Deerfield Management.
Funding History
Aug 2020
Sign up to see all 3 events
Funding: Venture Round through Corporate Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/es"><img src="https://indexed.vc/api/badge/company/es" alt="ES on Indexed.vc" width="260" height="76" /></a>